Evidence map›Paper›PMID 41194198›Full record

ArticleCancer cell international2025

Prognostic evaluation and experimental validation of cuproptosis-related hub genes identified through weighted gene co-expression network analysis in uveal melanoma.

Siying Chen, Nan Li, Boning Zeng, Yitong Guo, Guangqin Zhang, Chao Sun, Boqing Zhang, Qiuling Chen, Nan Li, Chaowei Zhu and 3 more

Abstract read
In one paragraph

Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Siying Chen *School of Pharmaceutical Sciences, Shenzhen University Medical School, Shenzhen 518000, China.
Nan Li *Department of Pharmacy, Cancer Hospital of Shantou University Medical College, Shantou, 515000, China.
Boning ZengDepartment of General Practice, Shenzhen Luohu People's Hospital, The Third Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China.
Yitong GuoSchool of Pharmaceutical Sciences, Shenzhen University Medical School, Shenzhen 518000, China.
Guangqin ZhangSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
Chao SunDepartment of Pharmacy, Shenzhen People's Hospital, (The First Affliated Hospital, Southern University of Science and Technology; The Second Clinical Medical College, Jinan University; State Key Laboratory of Neurology and Oncology Drug Development), Shenzhen, 518020, Guangdong, China.
Boqing ZhangDepartment of Pharmacy, Shenzhen People's Hospital, (The First Affliated Hospital, Southern University of Science and Technology; The Second Clinical Medical College, Jinan University; State Key Laboratory of Neurology and Oncology Drug Development), Shenzhen, 518020, Guangdong, China.
Qiuling ChenDepartment of Pharmacy, Shenzhen People's Hospital, (The First Affliated Hospital, Southern University of Science and Technology; The Second Clinical Medical College, Jinan University; State Key Laboratory of Neurology and Oncology Drug Development), Shenzhen, 518020, Guangdong, China.
Nan LiDepartment of Pharmacy, Shenzhen People's Hospital, (The First Affliated Hospital, Southern University of Science and Technology; The Second Clinical Medical College, Jinan University; State Key Laboratory of Neurology and Oncology Drug Development), Shenzhen, 518020, Guangdong, China.
Chaowei ZhuDepartment of Pharmacy, Shenzhen People's Hospital, (The First Affliated Hospital, Southern University of Science and Technology; The Second Clinical Medical College, Jinan University; State Key Laboratory of Neurology and Oncology Drug Development), Shenzhen, 518020, Guangdong, China.
Mingwei LiDepartment of Pharmacy, Shenzhen People's Hospital, (The First Affliated Hospital, Southern University of Science and Technology; The Second Clinical Medical College, Jinan University; State Key Laboratory of Neurology and Oncology Drug Development), Shenzhen, 518020, Guangdong, China. limingwei3003@163.com.
Xiao WangDepartment of Pharmacy, Shenzhen People's Hospital, (The First Affliated Hospital, Southern University of Science and Technology; The Second Clinical Medical College, Jinan University; State Key Laboratory of Neurology and Oncology Drug Development), Shenzhen, 518020, Guangdong, China. wangxiao0719@163.com.
Shaoxiang WangSchool of Pharmaceutical Sciences, Shenzhen University Medical School, Shenzhen 518000, China. wsx@szu.edu.cn.

Funding

China Postdoctoral Science Foundation No. 2022M722213Guangdong Province Clinical Drug Research Fund 2022JZ14National Natural Science Foundation of China-Guangdong Joint Fund 82073937, 32000516Shenzhen Key Medical Discipline Construction Fund SZXK059Shenzhen Science and Technology Project JCYJ20220818102605011, JCYJ20210324093602007, GJHZ20200731095200003 and JCYJ20190809165805604
6 · The paper itself

Abstract

backgroundUveal melanoma (UVM) is the most common primary intraocular malignancy, poses a formidable challenge due to its high metastatic potential and grim prognosis, but limited treatment options for UVM have prompted studies on immunotherapies. Cuproptosis is a recently discovered form of regulated cell death that has emerged as a potential regulator of the tumor microenvironment (TME) and a modulator of cancer development. However, the association between cuproptosis and UVM remains unclear.

methodsWeighted gene co-expression network analysis (WGCNA) was used to identify cuproptosis genes. Transcriptome correlation analysis and differential analysis were conducted following consensus clustering on 221 UVM samples. The objective was to identify cuproptosis-related genes (CRGs). Employing the LASSO Cox regression method, the identified CRGs were utilized to formulate a prognostic model termed CRG_score. Functional enrichment analysis was conducted to explore the biological processes linked to the CRG_score. Additionally, the research delved into the association between CRG_score and the responsiveness to chemotherapy drugs like docetaxel and etoposide. We also explored the effect of cuproptosis on UVM at the cellular level.

resultsUVM patients were classified into two distinct cuproptosis clusters, each exhibiting unique clinicopathological characteristics, prognostic outcomes, immune checkpoint expression levels, and immune infiltration patterns. CRGs were used to develop a prognostic model, CRG_score, with eight pivotal CRGs that accurately predicted the prognosis of UVM (AUC = 0.895). The single-cell RNA sequencing (scRNA-seq) analysis further confirmed the high tumor cell specificity of these eight model genes, validating the rationale for constructing the CRG_score. Functional enrichment analysis demonstrated that the CRG_score is associated with pathways involving cell signaling, immune responses, and metabolic regulation. A low CRG_score was associated with a favorable response to chemotherapy drugs such as docetaxel and etoposide. In cellular experiments, it was observed that the cuproptosis inducer elesclomol can impede the growth and proliferation of UVM cells, causing cell cycle arrest at the G2/M phase, as well as prompting apoptosis and the accumulation of reactive oxygen species (ROS).

conclusionCompared to several previous studies, we have extended the search for CRGs very rigorously in order to increase the value of cuproptosis in the prognosis and treatment of UVM. This whole transcriptome analysis elucidates the crucial role of cuproptosis-related molecular subtypes in the prognosis of UVM, highlights its association with the TME, and provides a scientific basis for clinical drug decisions.

Indexed as

CuproptosisImmune checkpoint inhibitorsMolecular subtypesTumor microenvironmentUveal melanoma prognosis

Identifiers

PMID41194198
PMCPMC12587622

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.